Goldman Sachs upgraded Roche (RHHBY) to Neutral from Sell with a price target of CHF 365, up from CHF 260. The firm cites reduced catalyst risks in 2026 relative to 2025 and improved growth potential, driven by giredestrant and fenebrutinib, but argues that this appears reflected in the current valuation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- White House releases details on Trump ‘Great Healthcare Plan’
- Street sees buying opportunity as Disc Medicine slips on FDA review delay
- Stifel sees weakness in Disc Medicine shares as buying opportunity
- Trump Trade: Trump administration moves to end pharma trade probe
- AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs